Literature DB >> 24509445

HBV life cycle is restricted in mouse hepatocytes expressing human NTCP.

Hanjie Li1, Qiuyu Zhuang1, Yuze Wang2, Tianying Zhang3, Jinghua Zhao3, Yali Zhang3, Junfang Zhang3, Yi Lin4, Quan Yuan3, Ningshao Xia3, Jiahuai Han1.   

Abstract

Recent studies have revealed that human sodium taurocholate cotransporting polypeptide (SLC10A1 or NTCP) is a functional cellular receptor for hepatitis B virus (HBV). However, whether human NTCP can support HBV infection in mouse hepatocyte cell lines has not been clarified. Because an HBV-permissible mouse model would be helpful for the study of HBV pathogenesis, it is necessary to investigate whether human NTCP supports the susceptibility of mouse hepatocyte cell lines to HBV. The results show that exogenous human NTCP expression can render non-susceptible HepG2 (human), Huh7 (human), Hepa1-6 (mouse), AML-12 (mouse) cell lines and primary mouse hepatocyte (PMH) cells susceptible to hepatitis D virus (HDV) which employs HBV envelope proteins. However, human NTCP could only introduce HBV susceptibility in human-derived HepG2 and Huh7 cells, but not in mouse-derived Hepa1-6, AML-12 or PMH cells. These data suggest that although human NTCP is a functional receptor that mediates HBV infection in human cells, it cannot support HBV infection in mouse hepatocytes. Our study indicated that the restriction of HBV in mouse hepatocytes likely occurs after viral entry but prior to viral transcription. We have excluded the role of mouse hepatocyte nuclear factors in the restriction of the HBV life cycle and showed that knockdown or inhibition of Sting, TBK1, IRF3 or IRF7, the components of the anti-viral signaling pathways, had no effect on HBV infection in mouse hepatocytes. Therefore, murine restriction factors that limit HBV infection need to be identified before a HBV-permissible mouse line can be created.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24509445      PMCID: PMC4003384          DOI: 10.1038/cmi.2013.66

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN: 1672-7681            Impact factor:   11.530


  28 in total

1.  Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication.

Authors:  S K Ladner; M J Otto; C S Barker; K Zaifert; G H Wang; J T Guo; C Seeger; R W King
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

Review 2.  Bile salt transporters.

Authors:  Peter J Meier; B Stieger
Journal:  Annu Rev Physiol       Date:  2002       Impact factor: 19.318

3.  A short N-proximal region in the large envelope protein harbors a determinant that contributes to the species specificity of human hepatitis B virus.

Authors:  P Chouteau; J Le Seyec; I Cannie; M Nassal; C Guguen-Guillouzo; P Gripon
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

4.  Large surface proteins of hepatitis B virus containing the pre-s sequence.

Authors:  K H Heermann; U Goldmann; W Schwartz; T Seyffarth; H Baumgarten; W H Gerlich
Journal:  J Virol       Date:  1984-11       Impact factor: 5.103

5.  Nuclear covalently closed circular viral genomic DNA in the liver of hepatocyte nuclear factor 1 alpha-null hepatitis B virus transgenic mice.

Authors:  A K Raney; C M Eggers; E F Kline; L G Guidotti; M Pontoglio; M Yaniv; A McLachlan
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

6.  Structural and functional characterization of liver cell-specific activity of the human sodium/taurocholate cotransporter.

Authors:  T Shiao; M Iwahashi; J Fortune; L Quattrochi; S Bowman; M Wick; I Qadri; F R Simon
Journal:  Genomics       Date:  2000-10-15       Impact factor: 5.736

7.  Role of liver-enriched transcription factors and nuclear receptors in regulating the human, mouse, and rat NTCP gene.

Authors:  Diana Jung; Bruno Hagenbuch; Michael Fried; Peter J Meier; Gerd A Kullak-Ublick
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2003-12-30       Impact factor: 4.052

8.  High-level hepatitis B virus replication in transgenic mice.

Authors:  L G Guidotti; B Matzke; H Schaller; F V Chisari
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

9.  Myristylation of the hepatitis B virus large surface protein is essential for viral infectivity.

Authors:  P Gripon; J Le Seyec; S Rumin; C Guguen-Guillouzo
Journal:  Virology       Date:  1995-11-10       Impact factor: 3.616

10.  Completion of the entire hepatitis C virus life cycle in genetically humanized mice.

Authors:  Marcus Dorner; Joshua A Horwitz; Bridget M Donovan; Rachael N Labitt; William C Budell; Tamar Friling; Alexander Vogt; Maria Teresa Catanese; Takashi Satoh; Taro Kawai; Shizuo Akira; Mansun Law; Charles M Rice; Alexander Ploss
Journal:  Nature       Date:  2013-07-31       Impact factor: 49.962

View more
  41 in total

Review 1.  Hepatitis delta virus: A fascinating and neglected pathogen.

Authors:  Celso Cunha; João Paulo Tavanez; Severin Gudima
Journal:  World J Virol       Date:  2015-11-12

2.  Preclinical assessment of antiviral combination therapy in a genetically humanized mouse model for hepatitis delta virus infection.

Authors:  Benjamin Y Winer; Elham Shirvani-Dastgerdi; Yaron Bram; Julie Sellau; Benjamin E Low; Heath Johnson; Tiffany Huang; Gabriela Hrebikova; Brigitte Heller; Yael Sharon; Katja Giersch; Sherif Gerges; Kathleen Seneca; Mihai-Alexandru Pais; Angela S Frankel; Luis Chiriboga; John Cullen; Ronald G Nahass; Marc Lutgehetmann; Jared E Toettcher; Michael V Wiles; Robert E Schwartz; Alexander Ploss
Journal:  Sci Transl Med       Date:  2018-06-27       Impact factor: 17.956

3.  Hepatitis B virus molecular biology and pathogenesis.

Authors:  R Jason Lamontagne; Sumedha Bagga; Michael J Bouchard
Journal:  Hepatoma Res       Date:  2016-07-01

4.  The Na(+)-Taurocholate Cotransporting Polypeptide Traffics with the Epidermal Growth Factor Receptor.

Authors:  Xintao Wang; Pijun Wang; Wenjun Wang; John W Murray; Allan W Wolkoff
Journal:  Traffic       Date:  2016-01-10       Impact factor: 6.215

5.  CMI: Highlights in last three years.

Authors:  Zhi-Qing Hu
Journal:  Cell Mol Immunol       Date:  2016-08-29       Impact factor: 11.530

6.  Role of Sodium Taurocholate Cotransporting Polypeptide as a New Reporter and Drug-Screening Platform: Implications for Preventing Hepatitis B Virus Infections.

Authors:  Menq-Rong Wu; Yi-You Huang; Jong-Kai Hsiao
Journal:  Mol Imaging Biol       Date:  2020-04       Impact factor: 3.488

7.  Preclinical Profile of AB-423, an Inhibitor of Hepatitis B Virus Pregenomic RNA Encapsidation.

Authors:  Nagraj Mani; Andrew G Cole; Janet R Phelps; Andrzej Ardzinski; Kyle D Cobarrubias; Andrea Cuconati; Bruce D Dorsey; Ellen Evangelista; Kristi Fan; Fang Guo; Haitao Guo; Ju-Tao Guo; Troy O Harasym; Salam Kadhim; Steven G Kultgen; Amy C H Lee; Alice H L Li; Quanxin Long; Sara A Majeski; Richeng Mao; Kevin D McClintock; Stephen P Reid; Rene Rijnbrand; Nicholas M Snead; Holly M Micolochick Steuer; Kim Stever; Sunny Tang; Xiaohe Wang; Qiong Zhao; Michael J Sofia
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

8.  Breaking the species barrier for hepatitis delta virus.

Authors:  Benjamin Y Winer; Alexander Ploss
Journal:  Hepatology       Date:  2015-10-29       Impact factor: 17.425

9.  In silico analysis and experimental validation of azelastine hydrochloride (N4) targeting sodium taurocholate co-transporting polypeptide (NTCP) in HBV therapy.

Authors:  L-L Fu; J Liu; Y Chen; F-T Wang; X Wen; H-Q Liu; M-Y Wang; L Ouyang; J Huang; J-K Bao; Y-Q Wei
Journal:  Cell Prolif       Date:  2014-06-26       Impact factor: 6.831

Review 10.  Hepatocarcinogenesis associated with hepatitis B, delta and C viruses.

Authors:  Elham Shirvani-Dastgerdi; Robert E Schwartz; Alexander Ploss
Journal:  Curr Opin Virol       Date:  2016-08-06       Impact factor: 7.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.